28 Oct 2020 ENHERTU (fam-trastuzumab deruxtecan-nxki) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer
27 Oct 2020 BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region
27 Oct 2020 CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)
26 Oct 2020 HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19
26 Oct 2020 CTA approval of BioInvent’s BI-1808, a first-in-class anti-TNFR2 antibody, sets stage for Phase I/IIa trial
26 Oct 2020 Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
26 Oct 2020 GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial
26 Oct 2020 NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 Antibody-Drug Conjugate for Patients with Solid Tumors
26 Oct 2020 Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings
23 Oct 2020 First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
23 Oct 2020 IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
22 Oct 2020 Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients
22 Oct 2020 Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells
22 Oct 2020 Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
21 Oct 2020 Chugai Enters into a License Agreement for Chugai’s Antibody Engineering Technologies with Novo Nordisk
21 Oct 2020 Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19
21 Oct 2020 Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)
21 Oct 2020 Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020
21 Oct 2020 Kineta Presents New Preclinical Data on its VISTA Antagonist Antibodies at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy
21 Oct 2020 NeuClone Announces Positive Results from Phase I Study of Stelara® (ustekinumab) Biosimilar Candidate
21 Oct 2020 Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
19 Oct 2020 NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4
19 Oct 2020 Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)
19 Oct 2020 VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors
19 Oct 2020 U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up